But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...

For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.

Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...

Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, antibiotics and other drugs to manage the sometimes debilitating symptoms. However, ...

Benralizumab is more effective than prednisolone in treating eosinophilic exacerbations in patients with asthma and COPD.

Argon Medical Devices, a leading provider of device solutions for Interventional Radiology, Vascular Surgery, Interventional ...

Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...

Sanofi’s Dupixent and new drugs drive growth, despite near-term pressures. See why SFY stock’s product pipeline makes it a ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...